Data as of 9:36am ET
| +2.60 / +1.06%|
Roche Holding AG manufactures, develops, and markets diagnostic and therapeutic products. The company focuses on pharmaceutical products and services for the early detection, prevention, diagnosis, and treatment of diseases. It offers in-vitro diagnostics and drugs for cancer, transplantation, autoimmune diseases, inflammatory diseases, virology, metabolic disorders and diseases of the central nervous system. The company operates through the following segments: Roche Diagnostics and Roche Pharmaceuticals. The Roche Diagnostics segment offers blood glucose meters for people with diabetes; point-of-care testing devices for use in doctor's offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and instruments and reagents for life science research. Its business areas include Roche Professional Diagnostics, which provides integrated cobas branded solutions for blood serum testing in commercial and hospital labs, medical centers, and laboratory networks and supports clinical products decision making in indication fields, including oncology, virology, cardiovascular, inflammatory and infectious diseases; Roche Diabetes Care that integrates glucose monitoring and data management with insulin delivery and helps people with diabetes live healthy, productive lives and to make managing diabetes easier; Roche Molecular Diagnostics, which develops and manufactures tests based on polymerase chain reaction technology; Roche Applied Science that supplies instruments and reagents and test kits for use in the life science research market and industrial applications; and Roche Tissue Diagnostics, which manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. The Roche Pharmaceuticals offers various products, including ACTEMRA, which is an interleukin-6 receptor-inhibiting monoclonal antibody developed for the treatment of rheumatoid arthritis; Bactrim used in the treatment of infections; CellCept, which is used in the prevention of organ rejection in patients receiving kidney, heart, and liver transplants; Dilatrend used for the treatment of hypertension and chronic heart failure; Fuzeon, offers antiretroviral medicinal products for the treatment of HIV infected patients; Lariam used in the prevention and treatment of malaria; MIRCERA, which is used to treat patients with symptomatic anemia associated with chronic kidney disease; Pegasys used in the treatment of patients with viral hepatitis; Valium, which is used in the treatment of anxiety disorders; and Zelboraf, which is an oral, small molecule, kinase inhibitor indicated for the treatment of patients with inoperable and metastatic melanoma. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
|Severin Schwan, LLD||Chief Executive Officer & Director|
|Alan Hippe, PhD||Chief Financial & Information Technology Officer|
|Per-Olof Attinger, MBA||Head-Chief Executive Officer Office|
|Hans-Joachim Boehm, PhD||Global Head-Chemistry|
|Sascha Bucher||Vice Director-Mergers & Acquisitions|